Security
BioStem Technologies, Inc. Common Stock · BSEM
BSEMNASDAQCommon stockHistorical · closed Oct 19, 2026CIK 1658678Updated Nov 19, 2026
BSEM price & chart
This listing closed Oct 19, 2026. Live provider charts are shown only for current listings.
Current security: BSEM
About the company
BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
In the news
Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform ↗
Recent filings
Offerings
Registration 333-299282
Registration 333-299025
Registration 333-297780
Filing attachments
bsem-ex99_1.htm · 8-K · 2026-11-12
Exhibit 99.1 BioStem Technologies Reports Third Quarter 2026 Financial Results; Grows Hospital Revenue for Second Consecutive Quarter as Customers Expand Use of Portfolio Hospital revenue grew sequentially to $6.8 million; customers purchasing two or more product lines up 14% from the second quarter In-house production of Neox® and Clarix® on track to begin in the first half of 2027 Raises full-year 2026 revenue guidance POMPANO BEACH, FL, November 12, 2026 (GLOBE NEWSWIRE) - BioStem Techno…
Read attachment ↗bsem-ex4_1.htm · 8-K · 2026-09-30
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSA…
Read attachment ↗bsem-ex99_1.htm · 8-K · 2026-09-30
Exhibit 99.1 BioStem Technologies Announces $3 Million Private Placement Priced At-The-Market Under Nasdaq Rules POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of th…
Read attachment ↗bsem-ex99_1.htm · 8-K · 2026-09-18
EX-99.1 4 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Secures Up to $40 Million in a Committed Equity Facility POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a $40 million Committed Equity Facility (the “CEF”)…
Read attachment ↗bsem-ex99_1.htm · 8-K · 2026-08-12
EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Reports Second Quarter 2026 Financial Results Generates 29% sequential revenue growth, increasing to $7.9 million; Raises full-year 2026 revenue guidance Uplists to Nasdaq Capital Market POMPANO BEACH, FL, August 12, 2026 (GLOBE NEWSWIRE) - BioStem Technologies, Inc. (Nasdaq: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allog…
Read attachment ↗bsem-ex99_1.htm · 8-K · 2026-08-07
EX-99.1 2 bsem-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 BioStem Technologies Announces Nasdaq Uplisting Trading to Commence on August 7, 2026 POMPANO BEACH, Fla., August 6, 2026 - BioStem Technologies Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that The Nasdaq Stock Market LLC (“Nasdaq”) has completed its review of the Company’…
Read attachment ↗